Nativel F, Detraz L, Mauduit N, Riche V-P, Desal H, Grimandi G
Pharmacy department, university hospital, 85, rue Saint Jacques, 44093 Nantes, France.
Neuroradiology department, university hospital, 44093 Nantes, France.
Rev Epidemiol Sante Publique. 2019 Nov;67(6):361-368. doi: 10.1016/j.respe.2019.08.003. Epub 2019 Oct 26.
Activity-based Funding can induce financial imbalances for health institutions if innovative medical devices (MD) used to perform acts are included in Diagnosis Related Groups (DRG) tariff. To be reimbursed in addition to the DRG tariff, innovative MD must have received a favorable evaluation by the French National Authority for Health (Haute Autorité de Santé) and be registered on the positive list. The aim of this study was to evaluate the expenses and incomes generated by each scenario (before and after the reimbursement of MD), and the financial reports. This study concerned the management of ischemic stroke by mechanical thrombectomy devices, in high-volume French hospital.
All patients who have had an acute ischemic stroke and admitted to the interventional neuroradiology unit between January 2016 and December 2017 were included retrospectively in this monocentric study. They were divided into four subgroups based on the severity of the DRG. The cost study was carried out using the French National Cost Study Methodology adjusted for the duration of the stays and by micro-costing on MD.
A total of 267 patients were included. Over the study period, the average cost of the hospital stay was €10,492±6364 for a refund of €9838±6749 per patient. The acts performed became profitable once the MD were registered on the positive list (€-1017±3551 vs. €560±2671; P<0.05). Despite this reimbursement, this activity remained in deficit for DRG lowest severity (level 1) patients (€-492±1244). Specific MD used for mechanical thrombectomy represented 37% of the total cost of stay.
The time required to evaluate MD reimbursement files is too long compared to their development. As a result, practitioners are in difficulty to be able to carry out acts according to the consensual practices of their learned societies, without causing any financial deficit of their institutions.
如果用于执行医疗行为的创新型医疗设备(MD)被纳入诊断相关分组(DRG)收费标准,基于活动的资金分配可能会导致医疗机构出现财务失衡。要在DRG收费标准之外获得报销,创新型MD必须获得法国国家卫生管理局(Haute Autorité de Santé)的有利评估并列入正面清单。本研究的目的是评估每种情况(MD报销前后)产生的费用和收入以及财务报告。本研究涉及法国大型医院中使用机械取栓设备治疗缺血性中风的管理情况。
本单中心研究回顾性纳入了2016年1月至2017年12月期间因急性缺血性中风入住介入神经放射科的所有患者。根据DRG的严重程度将他们分为四个亚组。成本研究采用根据住院时间调整的法国国家成本研究方法,并对MD进行微观成本核算。
共纳入267例患者。在研究期间,住院平均费用为10492±6364欧元,每位患者的报销费用为9838±6749欧元。一旦MD被列入正面清单,所执行的医疗行为就会盈利(-1017±3551欧元对560±2671欧元;P<0.05)。尽管有这笔报销费用,但对于DRG严重程度最低(1级)的患者,这项业务仍处于亏损状态(-492±1244欧元)。用于机械取栓的特定MD占住院总费用的37%。
与MD的研发速度相比,评估MD报销文件所需的时间过长。因此,从业者难以按照其专业学会的共识性做法开展医疗行为,同时又不导致其所在机构出现任何财务亏损。